EMBO Molecular Medicine (Aug 2021)
The state of the art of bispecific antibodies for treating human malignancies
- Shuhang Wang,
- Kun Chen,
- Qi Lei,
- Peiwen Ma,
- Andy Qingan Yuan,
- Yong Zhao,
- Youwei Jiang,
- Hong Fang,
- Shujun Xing,
- Yuan Fang,
- Ning Jiang,
- Huilei Miao,
- Minghui Zhang,
- Shujun Sun,
- Zicheng Yu,
- Wei Tao,
- Qi Zhu,
- Yingjie Nie,
- Ning Li
Affiliations
- Shuhang Wang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Kun Chen
- NHC Key Laboratory of Pulmonary Immunological Diseases is supported by the non‐profit Central Research Institute fund of Chinese Academy of Medical Sciences (2019PT320003), Guizhou Provincial People’s Hospital
- Qi Lei
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Peiwen Ma
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Andy Qingan Yuan
- Excyte Biopharma Ltd
- Yong Zhao
- Nanjing Umab‐biopharma Co., Ltd
- Youwei Jiang
- Hangzhou Genekine Biotech Co., Ltd
- Hong Fang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Shujun Xing
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Yuan Fang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Ning Jiang
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Huilei Miao
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Minghui Zhang
- Department of Medical Oncology, Harbin Medical University Cancer Hospital
- Shujun Sun
- Queen Mary School, Nanchang University
- Zicheng Yu
- Geneplus
- Wei Tao
- China Pharmaceutical University
- Qi Zhu
- China Pharmaceutical University
- Yingjie Nie
- NHC Key Laboratory of Pulmonary Immunological Diseases is supported by the non‐profit Central Research Institute fund of Chinese Academy of Medical Sciences (2019PT320003), Guizhou Provincial People’s Hospital
- Ning Li
- Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- DOI
- https://doi.org/10.15252/emmm.202114291
- Journal volume & issue
-
Vol. 13,
no. 9
pp. 1 – 13
Abstract
Abstract Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.
Keywords
- bispecific antibodies (bsAb)
- malignancies
- single‐chain variable fragment (scFvs)
- tumor associate antigen
- tumor‐specific antigen
